Jenner P - Search Results

1

Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.

Stocchi F, Ruggieri S, Carta A, Ryatt J, Quinn N, Jenner P, Marsden CD, Agnoli A. Stocchi F, et al. Among authors: jenner p. Mov Disord. 1992;7(3):249-56. doi: 10.1002/mds.870070311. Mov Disord. 1992. PMID: 1620143 Clinical Trial.

2

Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.

Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X. Temlett JA, et al. Among authors: jenner pg. Mov Disord. 1989;4(3):261-5. doi: 10.1002/mds.870040307. Mov Disord. 1989. PMID: 2571082

3

Oxyferriscorbone elevates the total iron content of blood but not brain.

Dexter DT, Jenner P, Marsden CD. Dexter DT, et al. Among authors: jenner p. Mov Disord. 1989;4(2):176-82. doi: 10.1002/mds.870040209. Mov Disord. 1989. PMID: 2733708

4

Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.

Nomoto M, Stahl S, Jenner P, Marsden CD. Nomoto M, et al. Among authors: jenner p. Mov Disord. 1987;2(1):37-45. doi: 10.1002/mds.870020105. Mov Disord. 1987. PMID: 2904119

5

The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.

Rose S, Jenner P, Marsden CD. Rose S, et al. Among authors: jenner p. Mov Disord. 1988;3(2):117-25. doi: 10.1002/mds.870030203. Mov Disord. 1988. PMID: 3221899

6

Chronic administration does not alter the accumulation of L-dopa into muscle.

Rose S, Jenner P, Marsden CD. Rose S, et al. Among authors: jenner p. Mov Disord. 1994 Mar;9(2):167-72. doi: 10.1002/mds.870090207. Mov Disord. 1994. PMID: 8196677

7

Debrisoquine hydroxylation in Parkinson's disease.

Steiger MJ, Lledo P, Quinn NP, Marsden CD, Turner P, Jenner PG. Steiger MJ, et al. Among authors: jenner pg. Acta Neurol Scand. 1992 Aug;86(2):159-64. doi: 10.1111/j.1600-0404.1992.tb05059.x. Acta Neurol Scand. 1992. PMID: 1414226

8

Levodopa in the treatment of Parkinson's disease: current controversies.

Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. Olanow CW, et al. Among authors: jenner p. Mov Disord. 2004 Sep;19(9):997-1005. doi: 10.1002/mds.20243. Mov Disord. 2004. PMID: 15372588 Review.

9

When do levodopa motor fluctuations first appear in Parkinson's disease?

Stocchi F, Jenner P, Obeso JA. Stocchi F, et al. Among authors: jenner p. Eur Neurol. 2010;63(5):257-66. doi: 10.1159/000300647. Epub 2010 Mar 24. Eur Neurol. 2010. PMID: 20332641 Review.

10

Mitochondrial DNA analysis in Parkinson's disease.

Schapira AH, Holt IJ, Sweeney M, Harding AE, Jenner P, Marsden CD. Schapira AH, et al. Among authors: jenner p. Mov Disord. 1990;5(4):294-7. doi: 10.1002/mds.870050406. Mov Disord. 1990. PMID: 1979656

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

771 results

Search Page

Filters